key: cord-0881591-ztpn0dig authors: Fonte, Luis; Acosta, Armando; Sarmiento, Maria E.; Ginori, María; García, Gissel; Norazmi, Mohd Nor title: COVID-19 Lethality in Sub-Saharan Africa and Helminth Immune Modulation date: 2020-10-08 journal: Front Immunol DOI: 10.3389/fimmu.2020.574910 sha: af4b18de682b37e4fdf2aee7241101c30a98c059 doc_id: 881591 cord_uid: ztpn0dig nan The acronym COVID-19 (Coronavirus Disease 2019) identifies the human disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (1). Since the outbreak of COVID-19 in Wuhan city, China, in December 2019, it has rapidly spread through 185 countries in all continents (2) . SARS CoV-2 infection, and its related disease, is now a major health problem, with 23,057,288 infected individuals and 800,906 deaths confirmed worldwide as of August 24, 2020 (3) . The natural progression of SARS CoV-2 infection is extremely variable. It ranges between an asymptomatic course or mild clinical expression, which generally occurs in children and healthy adults, and the development of pneumonia and severe multi-organ failure, more frequent in the elderly and in patients of chronic diseases. This broad spectrum of clinical expression is the consequence of another one at immunological level: SARS CoV-2 infection activates innate and adaptive immune responses that, in the most frequent and benign of evolutions, lead to the containment of viral replication and recovery and, in the most unfavorable of sequences, can stimulate an intense pulmonary inflammatory reaction that, leading to more severe complications, can end in death (4). SARS-CoV-2, unlike its close genetic relative SARS CoV, has the ability to infect and reproduce in the upper respiratory tract (5) . There, type I/III interferons, tumor necrosis factor alpha (TNF-α-) interleukin-1 (IL-1), IL-6, and IL-18, among other components of the innate immunity, control the infection in the majority of the individuals (6) . However, if SARS-CoV-2 passes through that first control and spreads, along the conducting airways, to the alveoli, it can replicate there more rapidly, causing pneumonia and other severe clinical complications (7) . Severe COVID-19 evolution is associated with an increase in the proportion of Th1 and Th17 cells, with their corresponding cytokines IFN-γ, IL17, IL-23, and TNF-α (8) . At the same time, there is an activation of the inflammatory CD14+CD16+ monocytes, with an amplified production of cytokines, such as IL-6, and chemokines, such as CC-chemokine ligand 2 (CCL2), CCL3 and CXC-chemokine ligand 10 (CXCL10) (8, 9) . The triggering of these cellular types, and the release of their mediators, leads to an increase of inflammation, vascular permeability and leakage with severe lung damage (8) . COVID-19 has shown significant differences in its lethality rate between continents, regions and countries (3) . Of them, the more notable is the higher rates registered in economically developed regions with robust health systems, such as Europe and the United States, compared to countries having poor economies and insufficient health services, in particular, almost all the nations that constitute the Sub-Saharan Africa (SSA) ( Table 1) (3). Some factors, or combinations of them, have been mentioned to explain the unexpected evolution: diagnostic test unavailability, age and genetic background of the population, mutational variations of SARS-CoV-2 in relation with geographic settings, environmental temperature and humidity non-favorable for viral replication, BCG vaccination policies and endemicity of other infections (10) (11) (12) . Here, we hypothesize the possible role of helminth immune modulation in the low COVID-19 lethality in SSA. In 2009, Hotez and Kamath, in a landmark paper analyzed the striking connection between living conditions and prevalence of Neglected Tropical Diseases (NTDs), linking the world's greatest concentration of poverty with helminth infection prevalence in SSA region (13) . In this region, "73% of the population lives on